03759 Overview

AI Impact on CRO/CDMO Sector: Investors are shifting focus towards AI disintermediating middlemen, with expectations that integrated CRDMO platforms will benefit more from AI than specialized CROs, which may face mixed effects from internal AI adoption.

CDMO Preference: CLSA favors CDMOs over CROs for better earnings visibility due to their capacity locking capabilities and long-term projects, with WUXI APPTEC, WUXI BIO, and PHARMARON highlighted as top picks in the sector.

Citi's Positive Catalyst Watch: Citi has initiated a 90-day positive catalyst watch on PHARMARON (03759.HK), highlighting upcoming announcements of last year's full-year results and accelerated order growth as key factors for optimism.

Buy Rating and Target Price: The broker has assigned a Buy rating to PHARMARON with a target price of HKD45, recognizing it as a global leader in drug research and development, particularly benefiting from the growth of China's CRO industry.

Expansion into New Areas: PHARMARON is not only maintaining its leadership in drug research but is also expanding into late-stage clinical development, commercial production, and the biopharmaceutical sector.

Market Activity: As of the latest data, short selling for PHARMARON stands at $7.59M with a ratio of 5.753%, indicating some market activity around the stock.

Top Shorted Stocks: S&P Global Market Intelligence identified the ten most shorted stocks in Hong Kong, with metrics based on the short selling ratio, which measures shares lent out relative to total issued shares.

Leading Stocks: COSCO SHIP HOLD topped the list with a short selling ratio of 40.396%, followed by DONGFANG ELEC and PHARMARON with ratios of 19.528% and 34.783%, respectively.

Stock Performance: The report includes recent price changes and short selling amounts, indicating varying performance among the listed stocks over the past week.

Market Insights: The data reflects investor sentiment and market dynamics, with significant short selling activity observed in companies like PING AN and ZTE, highlighting potential concerns or speculation in the market.

Stock Performance: PHARMARON (03759.HK) opened down 3.37% and is currently trading at $24, reflecting a 3.77% decrease with significant trading volume of 6.4042 million shares.

New Share Placement: The company announced a placement of approximately 58.4408 million new H shares at an 8.5% discount, aiming to raise nearly $1.32 billion in net proceeds.

Share Placement Announcement: Pharmaron plans to issue approximately 58.44 million new H-shares at HKD22.82 each, representing about 3.19% of its enlarged issued share capital and a 16.57% of total issued H-shares, at an 8.5% discount to the previous closing price.

Use of Proceeds: The company anticipates raising around HKD1.334 billion from the placement, with about 70% allocated for enhancing laboratory service facilities, drug process development, and production facilities.

US Stock Market Performance: US stocks fell 398 points (0.8%) following JPMorgan's earnings report, while chip stocks saw increased interest.

Hong Kong Market Opening: The Hong Kong bourse opened higher, with the HSI up 123 points (0.5%) and notable gains in tech stocks like BABA-W and TENCENT.

Inflation Rate in China: China's inflation rate for December was reported at 0.8%, slightly above the previous 0.7% but below the forecast of 0.9%.

Pharmaceutical Sector Activity: Several pharmaceutical stocks, including HANSOH PHARMA and BEONE MEDICINES, opened higher, while PHARMARON anticipated a decrease in full-year profit but still saw a slight increase in stock price.